Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated TCM Program for Metabolic Syndrome
NCT06703788Phase 2Recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ma Xing Shi Gan Tang and coptis chinensis in metabolic syndrome, sponsored by Chang Gung Memorial Hospital. Primary endpoint: The composite metabolic endpoint at 6 months. Started Nov 2024; status: recruiting.
02
Drugs
Ma Xing Shi Gan Tangcoptis chinensis
03
Conditions
metabolic syndrome
Beyond the preview
Go deeper on NCT06703788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703788.